Actively Recruiting
Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
Led by The First Affiliated Hospital of Dalian Medical University · Updated on 2024-07-12
466
Participants Needed
34
Research Sites
299 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Dalian Medical University
Lead Sponsor
H
Huazhong University of Science and Technology
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.
CONDITIONS
Official Title
Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed as primary glomerulonephritis by renal biopsy
- Male or female, 1864age6465
- Blood pressure can be effectively controlled at or below 140/90mmHg
- 30mL/min.1.73m264 eGFR<60mL/min.1.73m2
- 24-hour urine protein ration 64 2.0g/24h
- The participants must be capable of understanding and comply with the protocol and sign a written informed consent document
You will not qualify if you...
- Diagnosed as secondary glomerulonephritis
- Exposure to corticosteroids, immunosuppressors, tripterygium glycosides, ARBs or ACEIs, without a two weeks washout period
- Blood pressure < 90/60 mmHg
- Serum potassium > 5.5 mmol/L
- Serum albumin < 30g/L
- Unilateral or bilateral renal artery stenosis
- Pregnant or lactating women, and participants (including males) who were unable or unwilling to take adequate contraception during the study period
- Having comorbidities that affect the progression of primary glomerulonephritis (including but not limited to Malignant tumors, Systemic autoimmune diseases, Liver cirrhosis, Diabetes, and Gout)
- Allergic to the Huaiqihuang Granule or valsartan
- Participating in another clinical trial
- Investigators do not think it suitable for a participant to join this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 34 locations
1
Beijing Hospital
Beijing, Beijing Municipality, China, 100005
Actively Recruiting
2
Lanzhou University Second Hospital
Lanzhou, Gansu, China, 730030
Actively Recruiting
3
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China, 530021
Actively Recruiting
4
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China, 050000
Actively Recruiting
5
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei, China, 050000
Actively Recruiting
6
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150001
Actively Recruiting
7
Henan Provincial people's Hospital
Zhengzhou, Henan, China, 450003
Actively Recruiting
8
Xiangya Hospital of Central South University
Changsha, Hunan, China, 410000
Actively Recruiting
9
The first affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology
Baotou, Inner Mongolia, China, 014010
Actively Recruiting
10
Affiliated Hospital of Chifeng University
Chifeng, Inner Mongolia, China, 024000
Actively Recruiting
11
Changzhou NO.2 People's Hospital
Changzhou, Jiangsu, China, 213000
Actively Recruiting
12
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, China, 210000
Actively Recruiting
13
The First Bethune Hospital of Jilin University
Changchun, Jilin, China, 130000
Actively Recruiting
14
The Second Hospital of Jilin University
Changchun, Jilin, China, 130000
Actively Recruiting
15
Anshan Central Hospital
Anshan, Liaoning, China, 114000
Actively Recruiting
16
Anshan Shuangshan Hospital
Anshan, Liaoning, China, 114000
Actively Recruiting
17
Ansteel Group General Hospital
Anshan, Liaoning, China, 114000
Actively Recruiting
18
Benxi Iron and Steel General Hospital of Liaoning Health Industry Group
Benxi, Liaoning, China, 117000
Actively Recruiting
19
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China, 110001
Actively Recruiting
20
Dalian Ruikaier Nephropathy Hospital
Dalian, Liaoning, China, 116021
Actively Recruiting
21
Shengjing Hospital of China Medical University( Huaxiang Area)
Shenyang, Liaoning, China, 110000
Actively Recruiting
22
The First Hospital of China Medical University
Shenyang, Liaoning, China, 110000
Actively Recruiting
23
Central Hospital affiliated to Shenyang Medical College
Shenyang, Liaoning, China, 110010
Actively Recruiting
24
Shengjing Hospital of China Medical University (Nanhu Area)
Shenyang, Liaoning, China
Actively Recruiting
25
Yingkou Central Hospital
Yingkou, Liaoning, China, 115000
Actively Recruiting
26
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Actively Recruiting
27
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250000
Actively Recruiting
28
The Sixth People's Hospital affiliated to Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
29
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of medicine
Shanghai, Shanghai Municipality, China, 200092
Actively Recruiting
30
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China, 030013
Actively Recruiting
31
Shanxi Provincial people's Hospital
Taiyuan, Shanxi, China, 300012
Actively Recruiting
32
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China, 300211
Actively Recruiting
33
Kunming Yan'an Hospital
Kunming, Yunnan, China, 650000
Actively Recruiting
34
Zhejiang Provincial people's Hospital
Hangzhou, Zhejiang, China, 310014
Actively Recruiting
Research Team
H
Hongli Lin, MD
CONTACT
D
Dapeng Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here